Pay in 4 interest-free payments of $6.62 Learn more
Ships within 48 hours · Estimated delivery Aug 28 - Sep 2
Semaglutide 2.4 mg reduces the risk of major adverse cardiovascular events by 20% in adults with overweight or obesity in the SELECT trial [Press release]
The Clinical Data: Everything Published So Far Phase 1 First-in-Human (Oral Formulation) Published: The Lancet, June 2025 Participants: 144 adults with overweight or obesity (BMI 25.039.9), no diabetes Duration: Up to 12 weeks Dosing: Once-daily oral amycretin, up to 2 50 mg Results: - 50 mg dose: 10.4% mean body weight change - 2 50 mg dose: 13.1% mean body weight change - Placebo: 1.2% 13% weight loss in 12 weeks
Always consult with your healthcare provider to ensure this targeted metabolic support is the right fit for your unique, individual clinical picture as you navigate how to live with long-term COVID
Legitimate prescriptions should include appropriate pharmacy labeling, patient-specific information, dosing instructions, and prescribing clinician information
US$ 28.41
US$ 26.43
US$ 29.49
US$ 24.51
US$ 27.10
